Cannabinoids and uses thereof

Patent metadata

Field	Value
Publication number	US-12274678-B2
Application number	US-202017611093-A
Country	US
Kind code	B2
Filing date	May 17, 2020
Priority date	May 16, 2019
Publication date	Apr 15, 2025
Grant date	Apr 15, 2025

Abstract

The present invention provides a pharmaceutical composition including a combination of at least two cannabinoids, and methods of using same, such as for treating a NOTCH 1-related disease.

First claim

The invention claimed is:

1. A pharmaceutical composition comprising as an active ingredient a compound referred to as CF1 having the following chemical structure:

and a pharmaceutically acceptable carrier, wherein at least 5% of the cannabinoid content of the composition is CF1.

2. The pharmaceutical composition of claim 1 , wherein 100% of the cannabinoid content of the composition is CF1.

3. The pharmaceutical composition of claim 1 further comprising at least one additional cannabinoid selected from the group consisting of cannabidiol (CBD) and cannabidivarin (CBDV).

4. The pharmaceutical of claim 3 comprising CF1, CBD, and CBDV, wherein:
i. the weight per weight (w/w) ratio of CF1 to CBD ranges from 1:1 to 1:1,000;
ii. the w/w ratio of CF1 to CBDV ranges from 1:1 to 1:1,000; and
iii. the w/w ratio of CBDV to CBD ranges from 1:1 to 1:1,000.

5. The pharmaceutical composition of claim 4 , further comprising at least one additional cannabinoid selected from the group consisting of CBGA, CBG, CBG-C4, CBGV, CBGM, SesquiCBG, THC, 48-THC, THCV, CBDA, CBDA-C4, CBD-C4, CBDVA, CBDO, CBDM, CBCA, CBC, CBC-C4, CBCVA, CBCV, CBCO, CBN, CBNV, OH-CBN, CBEA, CBE, CBEV, CBND, CBNDA, CBL, CBT-1, CBTV-1, CBT-3, and CBT-2.

6. The pharmaceutical composition of claim 5 , wherein the w/w ratio of CF1, CBD, and CBDV combined to said at least one additional cannabinoid ranges from 10:1 to 100:1.

7. The pharmaceutical composition of claim 4 , further comprising at least one additional cannabinoid selected from the group consisting of THC, CBDA, and CBG.

8. The pharmaceutical composition of claim 7 , wherein the w/w ratio of CF1, CBD, and CBDV combined to said at least one additional cannabinoid ranges from 10:1 to 100:1.

9. The pharmaceutical composition of claim 4 , wherein CF1, CBD, and CBDV combined comprise at least 50% by weight of the cannabinoids in said composition.

10. The pharmaceutical composition of claim 4 , wherein one or more of the cannabinoids is present as a highly purified extract of Cannabis.

11. The pharmaceutical composition of claim 4 , wherein one or more of the cannabinoids is a synthetically produced cannabinoid.

12. A method for treating a subject afflicted with a NOTCH1-related disease, the method comprising administering to said subject a therapeutically effective amount of a pharmaceutical composition according to claim 3 .

13. The method of claim 12 , wherein said pharmaceutical composition comprises CF1 and CBD.

14. The method of claim 13 , wherein CF1 and CBD are present in said pharmaceutical composition in a weight per weight (w/w) ratio ranging from 1:1 to 1:1,000; or wherein CF1 and CBD are present in said pharmaceutical composition in a weight per weight (w/w) ratio ranging from 800:1 to 1:1.

15. The method of claim 12 , wherein said pharmaceutical composition comprises CF1 and CBDV.

16. The method of claim 15 , wherein CF1 and CBDV are present in said pharmaceutical composition in a weight per weight (w/w) ratio ranging from 1:1 to 1:1,000, or wherein CF1 and CBDV are present in said pharmaceutical composition in a weight per weight (w/w) ratio ranging from 1,000:1 to 1:1.

17. The method of claim 12 , wherein said pharmaceutical composition comprises CF1, CBD, and CBDV.

18. The method of claim 17 , wherein CBDV and CBD are present in said pharmaceutical composition in a weight per weight (w/w) ratio ranging from 1:1 to 1:1,000; or wherein CBDV and CBD are present in said pharmaceutical composition in a weight per weight (w/w) ratio of at least 100:1.

19. The method of claim 17 , wherein CF1, CBD, and CBDV are present in said pharmaceutical composition in a weight per weight (w/w) ratio ranging from 1:1:100 to 1:50:1,000.

20. The method of claim 12 , wherein said subject comprises an abnormal expression level of a NOTCH1 protein.

21. The method of claim 12 , wherein said NOTCH1-related disease is selected from the group consisting of leukemia, lymphoma, carcinoma, sarcoma, blastoma, and germ cells tumors.

22. The method of claim 12 , wherein said NOTCH1-related disease is selected from the group consisting of T cell acute lymphoblastic leukemia (T-ALL), Chronic lymphocytic leukemia (CLL), Melanoma, Cholangiocarcinoma (CCC), Colorectal cancer, Lung adenocarcinoma, Glioblastoma, Renal cell carcinoma, Ovarian cancer, Prostate cancer, Breast cancer, Pancreatic ductal adenocarcinoma (PDAC), Cervical cancer, Head and neck squamous cell carcinomas (HNSCC), Hepatocellular carcinoma (HCC), Medulloblastoma, B cell acute lymphoblastic leukemia (B-ALL), Acute myeloid leukemia (AML), Small cell lung carcinoma (SCLC), Lung squamous cell carcinoma (SqCC), Cutaneous squamous cell carcinoma (SqCC), and Chronic myelomonocytic leukemia (CMML).

23. The method of claim 22 , wherein said NOTCH1-related disease is T-ALL.

Assignees

• Technion Res & Dev Foundation
• Univ Ramot

Inventors

• Meiri David
• Besser Elazar
• Louria-Hayon Igal
• Berman Paula
• Lewitus Gil Moshe
• Broday Limor

Classifications

• A61K31/658 Primary

  o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61K31/05 Primary

  Phenols {(cannabinoids A61K31/658)} · CPC title